background: solid tumors may occur in 3% of the patients with chronic myeloid leukemia (cml). in this paper, we presented a case of cml following treatment of colon cancer. case presentation: a 25 year old man was diagnosed of adenocarcinoma of rectosigmoid treated with fluorouracil-based chemotherapy. following relapse, he received florouracil, oxaliplatin and irinotecan during the next year. ...

fms-like tyrosine kinase-3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system. mutations of fms-like tyrosine kinase-3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lymphoblastic leukemia. the fms-like tyrosine kinase-3 muta...

multi drug resistance(mdr) is a major problem in the treatment of cancer and hemalological malignancies. this resistance is multi factorial and is the result of decreased intra cellular drug accumulation. this is partly due to the presence of a 170kd intra membranous protein termed p-glycoprotein(p-gp) that is an energy-dependent efflux pump which has increased expression on drug-resistance cel...

The Leukemia & Lymphoma Society develops and distributes both detailed and easy-to-read booklets intended to help patients and caregivers communicate with healthcare providers about their treatment and support needs. The easy-to-read booklets initially were developed for newly diagnosed patients; however, the society has learned that all patients with cancer are likely to benefit from the infor...

Blast cells were obtained from 17 patients with acute undifferentiated leukemia and 13 patients with chronic myelogenous leukemia in blast crisis. The blasts were tested with anti-i serum in cytotoxicity tests and with antisera to myeloblastic leukemiaassociated antigens in immunofluorescence tests. The terminal deoxynucleotidyl transferase (TDT) content of the blasts was also measured. Lymphob...

In the prechemotherapy era arsenic derivatives were used for treatment of chronic myelogenous leukemia, a myeloproliferative disorder characterized by the t(9;22) translocation, the Philadelphia chromosome (Ph+). In acute promyelocytic leukemia response to arsenic trioxide (As2O3) has been shown to be genetically determined by the acute promyelocytic leukemia-specific t(15;17) translocation pro...

A man with acute myelogenous leukemia, treated with chemotherapy, had a decrease in circulating formed blood elements. Bone marrow biopsy revealed necrosis. Imaging with In-Ill chloride demonstrated activity in the liver, but not in the spleen or bone marrow. Eighteen days later, the circulating blood count had risen; a repeat bone marrow biopsy showed the return of blood cell precursors....

The purpose of this study was to define, in a phase I study in leukemia, the maximally tolerated dose (MTD), major toxicities, and possible antitumor activity of Topotecan, a new topoisomerase I (topo I) inhibitor. Topotecan was delivered by a 5-day continuous infusion every 3 to 4 weeks to patients with refractory or relapsed acute leukemia, at doses ranging from 3.5 mg/m2 to 18 mg/m2 per cour...